ClearPoint Neuro, Inc. (NASDAQ:CLPT) missed earnings with its latest second-quarter results, disappointing overly-optimistic forecasters. Unfortunately, ClearPoint Neuro delivered a serious earnings miss. Revenues of US$11m were 15% below expectations, and statutory losses ballooned 33% to US$0.38 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Taking into account the latest results, the most recent consensus for ClearPoint Neuro from three analysts is for revenues of US$48.9m in 2026. If met, it would imply a notable 16% increase on its revenue over the past 12 months. Per-share losses are supposed to see a sharp uptick, reaching US$1.32. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$53.1m and losses of US$1.11 per share in 2026. So it's pretty clear the analysts have mixed opinions on ClearPoint Neuro after this update; revenues were downgraded and per-share losses expected to increase.

The consensus price target fell 9.4% to US$25.67, with the analysts clearly concerned about the company following the weaker revenue and earnings outlook. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic ClearPoint Neuro analyst has a price target of US$30.00 per share, while the most pessimistic values it at US$22.00. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting ClearPoint Neuro's growth to accelerate, with the forecast 34% annualised growth to the end of 2026 ranking favourably alongside historical growth of 20% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 7.6% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect ClearPoint Neuro to grow faster than the wider industry.

The Bottom Line

The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at ClearPoint Neuro. They also downgraded ClearPoint Neuro's revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of ClearPoint Neuro's future valuation.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for ClearPoint Neuro going out to 2028, and you can see them free on our platform here..

Even so, be aware that ClearPoint Neuro is showing 4 warning signs in our investment analysis , and 1 of those can't be ignored...

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.